Keywords: Par Pharma, Handa Pharma, Takeda, Dexilant, US ANDA rights
Par Pharma acquires Handa's ANDA for generic Dexilant
Article | 23 April 2012
USA-based Par Pharmaceutical (NYSE: PRX) has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals to acquire its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
